Article PDF


transaminase, antituberculosis therapy, hepatotoxicity, mitochondrial dysfunction, polymorphism

Abstract views: 41
PDF Downloads: 5

How to Cite

Natrus , L., Gayova , L., Gorkunenko , O., Chernovol , P., & Zelinska , M. (2020). CYP2E1-DEPENDENT VARIATIONS IN HEPATOCYTES DAMAGE DURING TREATMENT OF TUBERCULOSIS. Medical Science of Ukraine (MSU), 16(3), 20-26.


Relevance. Investigation of polymorphism in a locus of CYP2E1 as the prognostic factor of drug-induced hepatotoxicity at anti-TB therapy is significant due to the influence of CYP2E1 on drug metabolism.

The objective of the investigation is to analyze the association of rs2070676 СYP2E1 gene polymorphism with drug-induced hepatotoxicity by means of the clinical-laboratory values of serum transaminases at anti-TB treatment.

Materials and methods. The study involved 47 patients with drug-susceptible tuberculosis first time discovered. 58 healthy volunteers comprised a control group. Laboratory indices were determined in venous blood three times: before the treatment as baseline; in 2 months of intensive therapy (isoniazid, rifampicin, ethambutol, pyrazinamide), then in 4 months of maintenance therapy (isoniazid, rifampicin). Serum activities of enzymes ALT, AST, and GGT were measured by standard algorithm on automatic analyzer BS-300. Analysis of rs2070676 polymorphism of CYP2E1 gene was performed by polymerase chain reaction using standard PureLink® Genomic DNA Kit for Purification of Genomic DNA; Manufacturer of INVITROGEN (USA). For statistical processing, IBM SPSS Statistics 23 was applied.

Results. Investigation of serum ALT and AST in patients with major genotype CYP2E1 (C/C) showed the lower baseline ALT and AST levels comparing to the control group, which might be caused by suppression of hepatocytes functions at the development of the disease. Anti-TB treatment caused an increase in ALT and AST levels comparing to the baseline in patients with major CYP2E1 (C/C) genotype. In the group with C/G polymorphism, the baseline ALT level didn’t differ much from the baseline of the control group; it showed a decrease after intensive therapy and returned back to the initial level at maintenance therapy. This might be related to the certain protective property of СYP2E1 gene polymorphism. The AST level was increased after intensive therapy (to a smaller extent than for the patients with major C/C genotype) and remained on the same level at maintenance therapy. A study of GGT showed a gradual increase regardless of genotype.

Conclusion. According to the data of the experiment, the status of hepatocytes in patients with tuberculosis at baseline and during treatment was different depending on the CYP2E1 genotype. The results of the experiment indicate that the CYP2E1 gene polymorphism has a certain protecting role. It reduces the level of drug metabolites and hepatotoxicity which causes mitochondrial dysfunction.
Article PDF


1. Saukkonen J.J., Cohn D.L, Jasmer R.M., Schenker S., Jereb J.A., Nolan Ch.M., Peloquin Ch.A., Gordin F.M., Nunes D., Strader D.B., Bernardo J., Venkataramanan R., Sterling T.R., ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med. 2006 Oct 15;174(8): 935-52. DOI:
2. Mirlohi M.-S., Ekrami A., Shirali S., Ghobeishavi M., Pourmotahari F. Hematological and liver toxicity of anti-tuberculosis drugs. Electron Physician. 2016 Sep; 8(9): 3005-10. DOI:
3. Wang P., Pradhan K., Zhong X., Xiaochao M. Isoniazid metabolism and hepatotoxicity. Acta Pharmaceutica Sinica B. 2016 Sep; 6(5): 384-92. DOI:
4. Boelsterli U.A., Lee K.K. Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress. Journal of Gastroenterology and Hepatology. 2014 Jan; 29(4): 678-87. DOI:
5. Metushi I.G., Nakagawa T., Uetrecht J. Direct Oxidation and Covalent Binding of Isoniazid to Rodent Liver and Human Hepatic Microsomes: Humans Are More Like Mice than Rats. Chem. Res. Toxicol. 2012 Nov 19; 25(11): 2567-76. DOI:
6. Bibi Z. Retracted: Role of cytorome P450 in drug interactions. Nutr. Metab. 2008 Oct 18; 5: Article number: 27 (2008). URL:
7. Preissner S.C., Hoffmann M.F., Preissner R., Dunkel M., Gewiess A., Preissner S. Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy. PLoS One. 2013; 8(12): e82562. DOI:
8. Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. Journal of Toxicology and Environmental Health. 2009; Part B; 12(5-6): 362-88. DOI:
9. Kurup R., Flemming K., Daniram S., Marks-James Sh., Martin R.R. Hematological and Biochemistry Profile and Risk Factors Associated with Pulmonary Tuberculosis Patients in Guyana. Tuberculosis Research and Treatment. 2016; 2016: article ID 6983747. DOI:
10. Agha M.A., El-Mahalawy I.I., Seleem H.M., Helwa M.A. Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. Egyptian Journal of Chest Diseases and Tuberculosis. 2014 Oct 14; 64(1): 91-6. DOI:
11. Pandit A., Pandey A.K. Liver Dysfunction in Pulmonary Tuberculosis Patients on DOTS: A Study and Review. Journal of Gastroenterology and Hepatology Research. 2016; 5(6): 2254-60. URL:
12. Mokondjimobe E., Longo-Mbenza B., Akiana J., Ndalla U.O., Dossou-Yovo R., Mboussa J., Parra H.-J. Biomarkers of Oxidative Stress and Personalized Treatment of Pulmonary Tuberculosis: Emerging Role of Gamma-Glutamyltransferase. Adv Pharmacol Sci. 2012; 2012: Article ID 465634. DOI:
13. Elinav E., Ben-Dov I.Z., Ackerman E., Kiderman A., Glikberg F., Shapira Y., Ackerman Z. Correlation Between Serum Alanine Aminotransferase Activity and Age: An Inverted U Curve Pattern // Am. J. Gastroenterol. 2005 Oct; 100(10): 2201-4. DOI:
14. Bekkelund S.I., Jorde R. Alanine Aminotransferase and Body Composition in Obese Men and Women Disease Markers. Hindawi. 2019; 2019: Article ID 1695874. DOI: URL:
15. Prati D., Taioli E., Zanella A., Torre E.D., Butelli, Vecchio E.D., Vianello L., Zanuso F., Mozzi F., Milani S., Conte D., Colombo M., Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2; 137(1): 1-10. DOI:
16. Burgert T.S., Taksali S.E., Dziura J., Goodman T.R., Yeckel C.W., Papademetris X., Constable R.T., Weiss R., Tamborlane W.V., Savoye M., Seyal A.A., Caprio S. Alanine Aminotransferase Levels and Fatty Liver in Childhood Obesity: Associations with Insulin Resistance, Adiponectin, and Visceral Fat. The Journal of Clinical Endocrinology & Metabolism. 2006 Nov; 91(11): 4287-94. DOI:
17. Kaminskaya G.О., Abdulaev R.Yu. Tuberculosis and lipid exchange. Tuberculosis and Lung Diseases. 2016; 94(6): 53-63. DOI:
18. Șahin F., Yildiz P. Distinctive biochemical changes in pulmonary tuberculosis and pneumonia. Arch. Med. Sci. 2013 Aug 30; 9(4):656-61. DOI:
19. Wilburn K.M., Fieweger R.A., VanderVen B.C. Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis. Pathogens and Disease. 2018 Mar 11; 76(2): fty021. DOI:
20. Queiroz A., Riley L.W. Bacterial immunostat: Mycobacterium tuberculosis lipids and their role in the host immune response. Rev. Soc. Bras. Med. Trop. 2017 Jan-Feb; 50(1): 9-18. DOI:
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.